NeoGenomics Inc.

AI Score

0

Unlock

13.87
1.24 (9.82%)
At close: Jan 14, 2025, 3:59 PM
13.78
-0.61%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 13.65
Market Cap 1.78B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.61
PE Ratio (ttm) -22.73
Forward PE n/a
Analyst Buy
Ask 13.95
Volume 2,355,067
Avg. Volume (20D) 782,360
Open 12.72
Previous Close 12.63
Day's Range 12.26 - 13.88
52-Week Range 12.13 - 19.11
Beta undefined

About NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fl...

Sector Healthcare
IPO Date Mar 16, 2004
Employees 2,100
Stock Exchange NASDAQ
Ticker Symbol NEO

Analyst Forecast

According to 10 analyst ratings, the average rating for NEO stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 40.64% from the latest price.

Buy 80.00%
Hold 20.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

NeoGenomics Inc. is scheduled to release its earnings on Feb 18, 2025, during market hours.
Analysts project revenue of $173.23M, reflecting a 11.36% YoY growth and earnings per share of 0.03, making a 0.00% YoY.
1 day ago · Source
-14.49%
NeoGenomics shares are trading lower after Benchma... Unlock content with Pro Subscription
4 days ago · Source
-20.63%
NeoGenomics shares are trading lower. The company announced its CEO will retire effective the first of April.